Financial Results
GKB Ophthalmics Publishes Q2 Results Extract
GKB Ophthalmics published newspaper extracts of its unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026.
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.


Bearish
2
Neutral
7
Bullish
5
Bearish
7
Neutral
7
Bullish
32
Bearish
5
Neutral
0
Bullish
27
Investor Presentation
Q2 FY26
Investor Presentation
Q4 FY25
GKB Ophthalmics Ltd (GKB) is currently trading at 63.60 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
GKB Ophthalmics Limited is an Indian manufacturer and trader of unfinished plastic ophthalmic lenses, operating since 1981 with an installed capacity of up to 35,000 lenses per day and a regular production run described as 25,000 lenses per day; the group also owns subsidiaries including Lensco and a European stock point historically to service export markets. The company reported standalone quarter revenue from operations of Rs. 539.69 lakhs for the quarter ended June 30, 2026, materially lower than the prior year quarter figure of Rs. 871.19 lakhs, and registered a consolidated total comprehensive loss for the quarter of approximately Rs. 55.29 lakhs, signaling demand or pricing pressure in the recent period. GKB recognized material past-service employee benefit liabilities tied to India’s new Labour Codes, with exceptional charges disclosed of Rs. 149.40 lakhs for the March quarter and Rs. 178.99 lakhs for the year ended March 31, 2026, reflecting a notable one-off accounting impact that management says it will monitor as central and state rules crystallise. The group has completed corporate rationalisation actions recently: the step-down subsidiary Prime Ophthalmics Products PTY Limited was closed on July 2, 2026 with an investment write-off of Rs. 43.50 lakhs, while earlier voluntary winding up of GSV Ophthalmics returned net proceeds to the holding company, impacting group structure and near-term profitability.
Over the past 52 weeks, GKB Ophthalmics Ltd has traded between a low of ₹45.25 and a high of ₹76.90. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
GKB Ophthalmics Ltd has a market capitalization of approximately 32.05. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
GKB Ophthalmics Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 6.54 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 32.05 Cr, GKB Ophthalmics Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
GKB Ophthalmics Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of GKB Ophthalmics Ltd is 6.54. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
GKB Ophthalmics reported basic and diluted loss per share of Rs 2.30 for the quarter ended September 30, 2026. The comparable loss per share was Rs 1.04 in the September 2025 quarter and Rs 0.96 in the June 2026 quarter.
GKB Ophthalmics reported consolidated profit of Rs 3.08 crore for the half year ended September 30, 2026. It reported Rs 1.20 crore in the corresponding half year ended September 30, 2025. Profit before tax increased to Rs 3.95 crore from Rs 1.35 crore.
GKB Ophthalmics has scheduled its next board meeting for November 12, 2026. Directors will consider unaudited standalone and consolidated results for the quarter and half year ended September 30, 2026.
Consolidated net sales were reported at Rs 29.79 crore for the quarter ended March 2026, down 3.97% from Rs 31.02 crore in the March 2025 quarter.
Healthcare Equipment & Supplies
Medical Equipment & Supplies
32 Cr
High Risk
6.5
60.1
0.1
0.6
76.90
45.25
Sales CAGR
Profit CAGR
ROE
ROCE
Financial Results
GKB Ophthalmics published newspaper extracts of its unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026.
Financial Results
GKB Ophthalmics reported unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026. Standalone quarterly loss before tax was 115.91.
Financial Results
GKB Ophthalmics recorded its unaudited standalone and consolidated results for the quarter and half year ended September 30, 2026, and decided to transition Unit II to a Domestic Tariff Area unit.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
